Best of ASCO - 2014 Annual Meeting

 

Welcome

Metastatic Non-Small Cell Lung Cancer

Lung Cancer—Non-Small Cell Metastatic

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
RET fusion in first/third-generation EGFR-TKIs resistance in advanced non-small cell lung cancer.

Yu Yao

e20634

A 18F-FDG PET/CT-based radiomics model predicts prognosis of synchronous oligometastatic non-small cell lung cancer.

Xiaoxia Zhu

e20610

A comparative analysis of survival in patients with non-small cell lung cancer with brain metastases receiving intracranial radiation with and without immunotherapy.

Sunita Patruni

9025

A joint model of tumor size dynamics and survival with new lesions in EGFR mutation-positive non-small cell lung cancer patients with treatment of gefitinib or carboplatin and paclitaxel.

James Dunyak

e20697

A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases.

Thiago Pimentel Muniz

e20604

A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer: TORG1833.

Yoshiro Nakahara

TPS9120

A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).

Yoshimasa Shiraishi

TPS9125

A novel algorithm to redefine blood-based tumor mutational burden for optimized prediction of clinical benefits from immunotherapy.

Zhijie Wang

e20514

A novel biophysical based marker with multilevel, multiparameter expression for early stage cancer detection.

Junjie Wu

e20673

A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.

Helena Alexandra Yu

9086

A phase I open prospective cohort trial of curcumin plus tyrosine kinase inhibitors for EGFR-mutant advanced non-small cell lung cancer.

Khashayar Esfahani

e20611

A phase I study to evaluate safety, tolerability, pharmacokinetics and antineoplastic activity of BPI-7711 in patients with EGFR/T790M mutation advanced or recurrent NSCLC.

Yuankai Shi

9034

A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.

Enriqueta Felip

9098

A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).

Taofeek Kunle Owonikoko

9022

A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).

Lyudmila Bazhenova

9014

A plasma miRNA signature classifier identifies PD-L1 ≥ 50% NSCLC nonresponders to immune checkpoint inhibitors.

Claudia Proto

9096

A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).

Takashi Seto

9003

A retrospective study evaluating clinical predictors of duration of response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.

Yahya Ibrahim

e20665

A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer.

Tong Zhou

e20666

Acquired resistance to MET inhibition in MET driven NSCLC.

Richard Riedel

9030

Activity of osimetrinib/AZD9291 in pretreated patients (pts) with epidermal growth factor receptor mutant (EGFRmt) non-small cell lung cancer (NSCLC), according to EGFR mutations detected in circulating plasma DNA (ctDNA).

Emmanouil Kontopodis

e20608

Adoption of immuno-oncology in NSCLC, a real-world study in EU5.

Alejandra Martinez De Pinillos

e20631

Afatinib in the treatment of advanced NSCLC with EGFR mutation: An observational real-world study.

Yun Li

e20518

Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies.

Kevin Smart

e20575

ALK resistance mutations and co-occurring genetic alterations to the ALK tyrosine kinase inhibitors in lung cancer.

Jin-Ji Yang

e20675

Analysis of a profile of lipid metabolism genes in advanced non-small cell lung cancer.

Maria Merino

e20619

Analysis of real-world data (RWD) on treatment (tx) sequencing in patients with advanced non-small cell lung cancer (aNSCLC).

Meng Ma

e20642

Angiotensin-converting enzyme inhibitor prescription is associated with decreased progression-free survival (PFS) and overall survival (OS) in patients with lung cancers treated with PD-1/PD-L1 immune checkpoint blockers.

Soleine Medjebar

e20512

Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1%.

Thierry Landre

9061

Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.

Pasi A. Janne

9007

Apparent diffusion coefficient and genetic mutations as effective indexes for radiotherapy time of brain metastases from lung cancer retrospective analysis.

Ruimei Ren

e20641

Association of allele frequency of EGFR mutation with efficacy of EGFR TKIs in advanced non-small cell lung cancer.

Xiang-Meng Li

e20678

Association of PFS with levels of pretreatment lactate dehydrogenase in patients with EML4-ALK rearrangement non-small cell lung cancer treated with ALK tyrosine kinase inhibitor.

Hongge Liang

e20513

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Ferdinandos Skoulidis

102

ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.

Enriqueta Felip

TPS9121

Autoantibodies indicating diagnostic or prognostic value in NSCLC patients were identified by protein microarrays.

Rongrong Luo

e20638

Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV non-squamous non-small cell lung cancer (STELLA): Design of a confirmatory, double-blind, randomized, controlled study.

Yaroslav V. Shparyk

e20731

BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response—Preliminary results from the NSCLC cohort.

Rieke Nila Fischer

e20550

Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.

Martin Gutierrez

TPS9117

Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.

Naiyer A. Rizvi

9016

Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).

Sally CM Lau

e20667

Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.

Myung-Ju Ahn

9026

Brigatinib in pretreated patients with ALK-positive advanced NSCLC.

Renaud Descourt

9045

Can texture analysis of pre-immunotherapy CT imaging predict clinical outcomes for patients with advanced NSCLC treated with Nivolumab?

Benjamin Oren Spieler

e20720

Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): A prospective, observational study.

Sofia Agelaki

9099

Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

Juergen Wolf

9004

CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach.

Raffaele Giusti

e20628

Characteristics of T-cell receptor repertoire between lung cancer patients and healthy people.

Naixin Liang

e20728

Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions.

Sai-Hong Ignatius Ou

9063

Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).

Wai Lin Thein

e20558

Chemoimmunotherapy combination: Potential option for metastatic NSCLC patients with EGFR mutation resistant to osimertinib.

Bo Yang

e20618

Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: A systematic review and literature-based meta-analysis.

Alfredo Addeo

e20565

Chemotherapy in KRAS-mutated chemotherapy naive non-small cell lung cancer patients: A phase III comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22 (NCT02743923).

Anne-Marie C. Dingemans

TPS9127

Circulating free DNA as a prognostic biomarker in patients with advanced ALK+ NSCLC treated with alectinib from the global phase III ALEX trial.

Rafal Dziadziuszko

9053

Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).

Justin F. Gainor

9008

Clinical benefit of EGFR-TKIs plus radiotherapy for treating EGFR-mutated metastatic non-small cell lung cancer.

Ran Lin Wang

e20694

Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC.

Giulia Pasello

e20612

Clinical haematological biomarkers: Derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) and their relationship to survival outcomes in non small cell lung cancer (NSCLC) treated with immunotherapy: A multicenter review.

Colum Dennehy

e20704

Clinical implication of inflammation-based serologic biomarkers and tissue biomarkers on hyperprogression in NSCLC patients receiving immune checkpoint blockers in real world.

Seoree KIM

e20633

Clinical implications of monitoring circulating tumor DNA in early- and late-stage non-small cell lung cancer patients.

Muyun Peng

e20607

Clinical importance of long noncoding RNA LINC00460 expression in plasma cell-free tumor RNA in EGFR-mutant adenocarcinoma.

Kazutoshi Isobe

e20529

Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).

Zofia Piotrowska

9069

Clinical outcomes of NSCLC patients with acquired RET rearrangement after resistance to osimertinib.

Chang Lu

e20626

Clinical outcomes of patients with or without common AEs in anlotinib cohort: Subgroup analysis of the ALTER0303 trial.

Wang Zhe-Hai

e20507

Clinical outcomes of various resistance mechanisms of osimertinib in Chinese advanced non-small cell lung cancer patients.

Puyuan Xing

e20530

Clinical predictors of efficacy for immune checkpoint inhibition in lung cancer patients.

Shijia Zhang

e20600

Clinical significance of Ki-67 index expression in advanced non-small cell lung cancer.

Di ming Wang

e20576

Clinical, pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer in a multicenter experience in Madrid: Final results.

Juan Moreno

e20621

Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study.

Tejas Patil

9090

Clonal evolution and osimertinib resistance mechanisms identified by whole exome and transcriptome sequencing in EGFR mutant NSCLC.

Nitin Roper

9049

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.

Rebecca Suk Heist

9023

Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.

Yong He

9035

Comparative genomic profiling of paired tissue and blood samples from advanced non-small cell lung cancer patients.

Xiaoyun Wang

e20521

Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer.

Hua Yang

e20534

Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in NSCLC.

Wenfeng Fang

e20536

Concurrent TP53 mutation adversely impact the efficacy of crizotinib in ROS1-rearranged lung cancer patients.

Lin Gen

e20535

Correlating the effects of VeriStrat result, anti-PD1 therapy, and neutrophil-to-lymphocyte ratio (NLR) on progression-free survival (PFS) in patients with stage IV non-small cell lung cancer (NSCLC).

Megan Randall

e20660

Correlation between PD-L1 level and immunotherapy outcome in NSCLC in Lebanon, 2012-2018: A multicenter observational review.

Ahmad Ghoche

e20524

Cost-effectiveness analysis of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.

Wenqian Li

e20556

Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).

Ashley Kim

e20703

Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer.

Wenqian Li

e20689

Cost-effectiveness of tyrosine kinase inhibition in first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer.

Jiaqi Han

e20504

Costs and hazard ratios of commonly used drugs in advanced/metastatic lung cancer at Cancer Free Foundation, Dana Point, California.

Helmy M. Guirgis

e20508

Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial–Updated report on progression-free and overall survival.

Sebastian Yves Friedrich Michels

9066

Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer.

Lan Shen

9101

Cross-sectional imaging utilization for EGFR, EML/ALK, and KRAS mutant non-small cell lung cancer.

Thomas Bomberger

e20663

Decreasing BMI/weight immediately prior to starting anti-PD-1/PDL-1 monoclonal antibodies for treatment for stage IV non-small cell lung cancer is associated with shorter progression-free survival.

Revathi Kollipara

e20710

Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer.

Sehhoon Park

9094

Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.

Libor Havel

9039

Determinants of early discontinuation of first-line chemotherapy, and associated outcomes among elderly with advanced non-small cell lung cancer.

Pramit Nadpara

9102

Development and validation of a deep learning model to assess tumor progression to immunotherapy.

Yi Yang

e20601

Distinct resistant mechanism and genomic evolution during TKI treatment in non-small cell lung cancer patients with or without acquired T790M mutation.

Ying Jin

e20603

Diverse RB1 mutations and co-occurring molecular alterations in advanced NSCLC.

Jie Huang

e20672

DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).

Hirva Mamdani

9100

DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.

Biagio Ricciuti

9077

Does the extent of brain metastasis affect outcome of non-small cell lung cancer patients treated with chemotherapy?

Yong Won Choi

e20616

Early assessment of therapy response in non-small cell lung cancer (NSCLC) via longitudinal ctDNA analysis.

Xiaoju Max Ma

e20701

Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).

Alice Tsang Shaw

9019

Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.

Caicun Zhou

9020

Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels.

Markus Joerger

e20661

Early mortality in metastatic lung cancer: A SEER population data analysis.

Opher Globus

9103

EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.

Sebastian Yves Friedrich Michels

e20577

ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.

Suresh S. Ramalingam

9002

Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).

Briana Choi

e20714

Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS).

Nimer S Alkhatib

e20515

Effect of a multi-disciplinary approach and incorporation of reflex testing on genomic profiling of non-squamous lung cancer in a community oncology practice.

Niraj K. Gupta

e20719

Effect of body mass index and age on survival in patients with advanced lung cancer treated with anti-PD-1 immune checkpoint inhibitors.

Corentin Richard

e20676

Effect of concurrent TP53 mutation in EGFR/ALK/ROS1 positive non-small cell lung cancer treated with first-line TKI therapy: A Single Institution Retrospective Study.

Sandhya Sharma

e20592

Effect of immunotherapy at any line of treatment on survival in Hispanic patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).

Andres Felipe Cardona Zorrilla

e20637

Efficacy and safety of Crizotinib in patients with ALK positive non small cell lung cancer (NSCLC): Real-world findings.

Cristina Azpitarte Raposeiras

e20636

Efficacy and safety of IBI305 compared with bevacizumab in advanced non-squamous NSCLC patients as first-line treatment in a randomized, double-blind, phase III study.

Li Zhang

9095

Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel with or without bevacizumab as second-line therapy or beyond for patients with metastatic non-small-cell lung cancer.

Fan Zhang

e20517

Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild‐type EGFR and ALK.

Caicun Zhou

9112

Efficacy of platinum-pemetrexed combination chemotherapy in ALK+ non-small cell lung cancer refractory to second-generation ALK TKIs.

Jessica Jiyeong Lin

9067

Efficacy of ramucirumab and docetaxel given either before or after immune checkpoint inhibitors in patients with lung cancers.

Michael Offin

9078

EGFR extracellular domain mutation in patients with lung cancer.

Renhua Guo

e20532

EGFR-A763_Y764insFQEA: A unique exon 20 insertion mutation that displays sensitivity to all classes of approved lung cancer EGFR tyrosine kinase inhibitors.

Carol Gergis

e20593

Erlotinib monotherapy in the treatment of advanced non-small cell lung carcinoma: A single center experience with 187 patients from 2005-2018.

Felipe Matsunaga

e20718

Estimating long-term survival of previously untreated patients with EGFR mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC) who received osimertinib in the FLAURA study.

Matthew Dyer

e20560

Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.

Bassel Nazha

9042

Evaluation of clonal hematopoiesis in late stage NSCLC using a next-generation sequencing panel targeting cancer genes.

Stephanie J. Yaung

9050

Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).

Roberto Ferrara

9107

FDA analysis of outcomes in Asian patients (pts) with metastatic non-small cell lung cancer (mNSCLC) receiving immune checkpoint inhibitors (ICI).

Elaine Chang

e20690

Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC).

Takashi Seto

9092

First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.

David Planchard

9054

First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.

Jacob M. Sands

9051

First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).

Anas Gazzah

9072

Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.

Edward B. Garon

LBA9015

Galician lung cancer group: Afatinib´s data as first-line treatment for elderly patients.

Sara Agraso Busto

e20662

Health care utilization associated with adverse events (AEs) among metastatic non-small cell lung cancer (mNSCLC) patients treated with immunotherapy or chemotherapy.

Nicole Engel-Nitz

e20655

Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC).

Rosario Garcia Campelo

9084

Homeless outcomes in non-small cell lung cancer: A county hospital experience.

Kyle Concannon

e20582

Identification and use of treatment (tx) options in patients (pts) with advanced non-small cell lung cancer (aNSCLC) after comprehensive genomic profiling (CGP): A real-world study.

Celine Mascaux

9076

Immune gene expression and bayesian network analysis in advanced non small cell lung cancer (NSCLC) patients treated with immunotherapy.

Sara Baglivo

e20693

Immune related adverse events in NSCLC patients treated with immune checkpoint therapy who received the influenza vaccination versus no vaccination.

Haritha G. Reddy

e20657

Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology.

Diego Signorelli

9106

Immunohistochemical expression of GRP78 in relation to angiogenesis markers VEGF-a and CD31 and other histopathological parameters in NSCLC.

Maha S. Al-Keilani

e20500

Immunotherapeutic efficacy in NSCLC and patients’ smoking status: A meta-analysis.

Shanshan Wang

e20510

Immunotherapy plus chemotherapy versus chemotherapy alone in metastatic non–small-cell lung cancer: A systematic review with meta-analysis.

Andre Deeke Sasse

e20700

Impact of antibiotics (ABX) on overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (aNSCLC) and melanoma (aMel) treated with first-line immune checkpoint inhibition (ICI).

Stephen Joseph Bagley

e20643

Impact of antibiotics and proton pump inhibitors on clinical outcomes of immune check point blockers in advanced non-small cell lung cancers and metastatic renal cell cancer.

Amit Kulkarni

e20520

Impact of baseline number of metastases on the efficacy of PD-1 inhibitor monotherapy for non-small cell lung cancer with high PD-L1 expression.

Taichi Miyawaki

e20551

Impact of cholesterolemia and body mass index on outcome of metastatic non small cell lung cancer treated with immunotherapy.

Giulia Galli

e20691

Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.

Hiroe Kayatani

9056

Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.

Biagio Ricciuti

9082

Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib.

Jia-Tao Cheng

e20726

Impact of time to treatment initiation (TTI) on survival of patients with newly diagnosed non-small cell lung cancer (NSCLC).

Abdel-Ghani Azzouqa

9058

IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).

Mark A. Socinski

9012

Improvement of lung cancer risk prediction adding SNPs to the HUNT Lung Cancer Model: A HUNT Study.

Oluf D. Røe

e20696

Incidence and patterns of immune related adverse events (irAEs) during chemoimmunotherapy (ChemoIO) in patients with advanced nonsquamous NSCLC.

Pradnya Dinkar Patil

e20705

Initiation of targeted therapy based on ctDNA only in metastatic NSCLC.

Jean Gabriel Bustamante Alvarez

e20687

Interim report on CIV recombinant human endostatin in combination with docetaxel/cisplatin (DP)) in comparison to DP in the first-line treatment of phase IIIb/IV squamous-cell NSCLC (JSLCG-001): A multicenter, open-label, randomized phase III controlled study (NCT: 02513342).

Jian'An Huang

e20541

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

Eric B. Haura

9009

KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.

Shirish M. Gadgeel

9013

Landscape of lung cancer molecular biology in a NON-selected population.

Rosa Ana Marcos

e20648

Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.

Myung-Ju Ahn

9037

Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.

Ibiayi Dagogo-Jack

9068

Matching insurance claims data with EMR molecular status data in non-small cell lung cancer (NSCLC) patients: Understanding real-world molecular testing and prevalence rates at the site and investigator level.

Michael Gregory Cushion

e20568

Mature, real world progression-free survival (PFS) and overall survival (OS) milestones in stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) followed by pem+/-bevacizumab(Bev) maintenance.

Parva Kiran Bhatt

e20721

Mechanisms of primary resistance to icotinib in Chinese non-small-cell lung cancer patients with EGFR uncommon mutations: A multicenter study.

Wen xian Wang

e20501

MET inhibitor resistance in patients with MET exon 14-altered lung cancers.

Robin Guo

9006

MET second-site mutations in EGFR-mutant, MET-amplified non-small cell lung cancer after resistance to combinatorial targeted therapy.

Jia-Tao Cheng

e20730

Methylation profiling of EGFR mutant primary and metastatic lung cancer with brain metastasis.

Yasin Mamatjan

e20574

miR-200c in extracellular vesicles as a circulating biomarker of EGFR-TKI response and a mediator of EGFR-TKI sensitivity in heterogeneous NSCLC.

Chienchung Lin

e20547

ml-RECIST: Machine learning to estimate RECIST in patients with NSCLC treated with PD-(L)1 blockade.

Kathryn Cecilia Arbour

9052

Model-driven metronomic vinorelbine in heavily pre-treated metastatic NSCLC and PM patients: Results of a phase I/II study.

Joseph Ciccolini

e20505

Molecular correlates of PD-L1 expression in patients with non-small cell lung cancer.

Hira Rizvi

9018

Molecular profiling as predictor of outcomes in a Brazilian cohort of stage IV lung cancer.

Nicolas Peruzzo

e20668

MS201944-0170: A phase IIa study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.

Fortunato Ciardiello

TPS9123

Multicenter observational prospective study of nivolumab (Nivo) as 2+ line treatment in advanced refractory NSCLC pts: Clinical and quality of life outcomes.

Rashida Orlova

e20567

Multiple mutations in the EGFR gene in patients diagnosed with lung cancer.

Ekaterina P. Omelchuk

e20542

Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.

Sally CM Lau

e20594

Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.

Zhenyu Ding

e20674

Neutrophils lymphocyte ratio role in predicting response to checkpoint inhibitors in metastatic non-small lung cancer.

Hosam Hakim

e20646

Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Preliminary efficacy and safety results of the non-interventional study VARGADO.

Christian Grohé

9074

Nomogram based on multivariable regression model estimates the overall survival of patients with nivolumab who were previously treated for advanced non-small cell lung cancer.

Motohiro Tamiya

e20683

Non-small cell lung cancer (NSCLC) case study examining whether results in a randomized control arm are replicated by a synthetic control arm (SCA).

Ruthie Davi

9108

NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.

Michaël Duruisseaux

9081

NTRK1 fusion identified by capture-based next-generation sequencing in non-small-cell lung cancer.

Ruiying Zhao

e20664

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

Myung-Ju Ahn

TPS9126

Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: An ETCTN California cancer consortium phase I study.

Jonathan W. Riess

9057

Osimertinib induced cardio-toxicity: A retrospective review of FDA adverse events reporting system (FAERS).

Kartik Anand

9044

Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.

Joel W. Neal

9083

Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.

Elizabeth Jimenez Aguilar

9111

Overall survival in PEMVITASTART randomized trial comparing immediate vs. conventional strategies of vitamin supplementation in NSCLC patients on 1st line pemetrexed-platinum chemotherapy.

Navneet Singh

e20538

Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.

Diana S.Y. Abdulla

e20682

Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Eugene R Ahn

9041

Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.

Edward B. Garon

9048

PD-1 antibody pembrolizumab administered at non-standard frequency in non-small cell lung cancer (NSCLC).

Kartik Sehgal

e20617

PD-1 versus PD-L1 inhibitors for previously treated advanced non-small cell lung cancer (NSCLC): Bayesian network meta-analysis (NMA).

Abdulaali Almutairi

e20511

PD-1/PD-L1 immunotherapy for advanced lung cancer: An electronic medical database based real world study in China.

Xiao Zhao

e20543

Pembrolizumab (Pem) for advanced non-small cell lung cancer (aNSCLC): Efficacy and safety in everyday clinical practice.

Doran Ksienski

e20506

Pembrolizumab alone or with chemotherapy for PD-L1 positive NSCLC: A network meta-analysis of randomized trials.

Mark Doherty

9087

Peripheral neuropathy among patients with NSCLC undergoing chemotherapy.

Jerzy Edward Tyczynski

e20552

Phase (Ph) I/II study of pembrolizumab (P) with gemcitabine (G) in patients (pts) with previously-treated advanced (Adv) non-small cell lung cancer (NSCLC).

Rachel E. Sanborn

e20652

Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)–deficient non-squamous non-small cell lung cancer.

Akhila Ganeshi Wimalasingham

9097

Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.

Edward S. Kim

TPS9115

Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.

Andreas Nicholas Saltos

9073

Phase Ib study of sintilimab in combination with chemotherapy for 1L advanced or metastatic non-small cell lung cancer (NSCLC).

Nong Xu

e20546

Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).

Mark M. Awad

9029

Phase II multicenter study of antroquinonol in patients with stage IV non-small cell lung cancer who have failed at least two lines of anti-cancer therapy.

Ching-Liang Ho

e20522

Phase II randomized trial of afatinib with or without cetuximab as first-line treatment for EGFR mutated non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung).

Alexis B. Cortot

9079

Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).

Saiama Naheed Waqar

9075

Phase II study of apatinib combined with vinorelbine in second-line treatment failure non-driver gene mutation advanced non-small cell lung cancer (NCT03652857).

Yongchang Zhang

e20669

Phase II study of tepotinib in NSCLC patients with METex14 mutations.

Paul K. Paik

9005

Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).

Vanita Noronha

9001

Platinum based chemotherapy in elderly patients with non-small cell lung carcinoma (NSCLC): Experience from an Indian tertiary cancer center.

Aparna Sharma

e20528

Pooled subgroup analysis of twelve randomized controlled trials of immunotherapy in non-small cell lung cancer.

Fang Yang

e20639

Potential interaction of radiation therapy, antibiotic, and steroid use in non-small cell lung cancer patients treated with checkpoint inhibitors: A retrospective analysis.

Fen Wang

e20724

Precision medicine and actionable alterations in lung cancer.

Isa Mambetsariev

e20707

Precision medicine for lung cancer decision-making: Evaluation of an -omics based FFT approach to personalized medicine.

Isa Mambetsariev

e20713

Prediction of EGFR-TKI efficacy in non-small cell lung cancer patients by metabolomics and genomics.

Lei Zhang

e20627

Predictors of benefits to chemoimmunotherapy (CIT) in stage IV non-small-cell lung cancer (NSCLC): A meta-analysis.

Hazem Edmond El-Osta

e20595

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

Julie R. Brahmer

9093

Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC).

Tom Stinchcombe

9027

Prognostic significance of radiologic features of pneumonitis induced by anti-PD-1 therapy.

Satoshi Watanabe

9065

Project Switch: Docetaxel as a potential synthetic control in metastatic non-small cell lung cancer (mNSCLC) trials.

Michael E. Menefee

9105

Prospective study of germline and somatic alterations for Early Onset LUNG cancer patients (EOLUNG MASTER protocol).

Maria Jove

TPS9122

Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes.

Alexandra Pender

9080

Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in non-small cell lung cancer: A real-world study.

Fang Wu

e20640

Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).

Thomas A. Hensing

9088

Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).

Myung-Ju Ahn

TPS9114

Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L).

Kaoru Tanaka

e20531

Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer.

James William Welsh

9104

Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L).

Isamu Okamoto

9031

Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006.

Rina Hui

TPS9118

Real-world (rw) clinical outcomes for advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) treated with second line (2L) ramucirumab plus docetaxel (R+D) post frontline (1L) platinum based chemotherapy plus immune checkpoint inhibitors (Pt + ICI).

Jeffrey Melson Clarke

e20727

Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor.

Sean Khozin

9110

Real-world characterization of advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) with rapid disease progression (RDP).

Martin Gutierrez

e20706

Real-world clinical burden of aggressive disease (AD) in advanced/metastatic non small cell lung cancer (aNSCLC).

Marta Batus

e20723

Real-world clinical experience of the Galician Lung Cancer Group: Afatinib in patients with EGFR positive mutation.

Sara Agraso Busto

e20654

Real-world economic burden of rapid disease progression (RDP) in patients (pts) with advanced/metastatic non-small cell lung cancer (aNSCLC).

Stacey DaCosta Byfield

e20716

Real-world immuno-oncology treatment patterns and outcomes in US patients with metastatic non-small-cell lung cancer.

Amanda Bruno

e20537

Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Sean Khozin

110

Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.

Michael Leapman

9059

Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients.

Yan Wang

9043

Real-world treatment patterns, survival, and cost among elderly patients with small-cell lung cancer (SCLC).

Changxia Shao

e20647

Real-world tumor response (rwTR) to ramucirumab plus docetaxel (R+D) post platinum-based (Pt) and immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (aNSCLC) patients (pts).

Jeffrey Melson Clarke

e20725

Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.

Gregory J. Riely

9062

Rebiopsy in patients with or without prior TKIs revealed complicated histology of lung cancer.

Kuikui Zhu

e20525

RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Kazuhiko Nakagawa

9000

S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).

Shirish M. Gadgeel

9021

Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).

Qing Zhou

9091

Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.

Pasi A. Janne

9010

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).

Byoung Chul Cho

9011

SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.

Geoffrey R. Oxnard

TPS9119

Sex is a strong prognostic factor for overall survival in advanced non small cell lung cancer patients and should be considered for survival rates estimations.

Miguel Barquin

e20580

SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).

Lecia V. Sequist

9036

Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.

Guanghui Gao

9089

Soluble biomarker signature to predict outcome of patients with non-small-cell lung cancer (NSCLC) treated with anti-PD1/PDL1 monoclonal antibodies.

Javier Garde-Noguera

e20685

Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).

Lingzhi Hong

9017

Survival analysis of anticoagulant treatment of non-small cell lung cancer.

Junyan Wang

e20623

TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma.

Alice Davies

TPS9116

Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.

Paul K. Paik

9085

The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).

Luis G. Paz-Ares

TPS9124

The clinical analysis of pulmonary lymphoepithelioma-like carcinoma with epithelioid granuloma: Fourteen cases and literature review.

Yinyin Qin

e20545

The clinical prognostic factors in advanced lung adenocarcinoma patients with different EGFR mutation subtype.

Yudong Wang

e20680

The continued osimertinib plus chemotherapy overcoming resistance after histologic transformation in EGFR-mutant lung adenocarcinoma treated with osimertinib.

Jin Kang

e20615

The depth of response was associated with the progression-free survival in advanced non-small cell lung cancer patients treated with EGFR-TKI.

Yutao Liu

e20509

The efficacy and safety of extended use of endostatin plus platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer: An analysis of a 10-year retrospective study.

Jing Zhao

e20523

The efficacy of ado-trastuzumab emtansine in patients with HER-2-aberrant non-small cell lung cancer.

Yang Xia

e20584

The efficacy of anlotinib in squamous cell carcinoma (SCC) patients with or without hypertension in ALTER0303: Anlotinib as a third-line therapy in patients with advanced non-small cell lung cancer (NSCLC).

Jianhua Shi

e20503

The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.

Kiyotaka Yoh

9046

The HGF-MET signaling pathway is enriched in LUAC brain metastases.

Maria A Velez

e20597

The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).

Kentaro Ito

9038

The impact of steroid use on efficacy of immunotherapy among patients with lung cancer who have developed immune-related adverse events.

Kazushige Wakuda

e20583

The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study.

Yoon Ho Ko

e20572

The interplay between PD-L1 and vimentin in NSCLC patients: An exploratory analysis.

Giuseppe Bronte

e20688

The molecular and immune characteristics, antitumor activity of crizotinib in non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations.

Jiadi Gan

e20588

The mutation profile of EGFR in resectable Chinese lung cancer patients.

Wenjun Mao

e20519

The role of low dose aspirin, vitamin D, or metformin in EGFR, ALK, and ROS positive non-small cell lung cancer: A single institution retrospective analysis.

Carolina Bernabe Ramirez

e20656

The use of liquid and tissue biopsy genomic testing in lung cancer: A single-institution experience.

Natalia Marina

e20692

Therapeutic and prognostic impacts of specific gene alterations for squamous cell lung cancer: A result of nationwide genome screening in Japan (LC-SCRUM-Japan).

Terufumi Kato

9060

Therapeutic efficacy comparison of six major EGFR-TKIs in non-small-cell lung cancer patients with an activating EGFR mutation: A network meta-analysis.

Fang Wu

e20671

Third and successive–lines of chemotherapy in NSCLC patients without therapeutic targets: Experience of the Grupo Gallego de Cáncer de Pulmón.

Francisco Javier Afonso Afonso

e20579

Time from stereotactic body radiotherapy to immunotherapy as a predictor for outcome in metastatic non small cell lung cancer.

Rodney E Wegner

9024

Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients.

Robert Charles Doebele

9070

Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.

Adam Jacob Schoenfeld

9028

Totality of evidence in development of the bevacizumab biosimilar ABP 215: Central and investigator evaluation of efficacy from the MAPLE study.

Michael Thomas

e20708

TP53 mutations in EGFR mt+ NSCLC IV as a predictive factor for ORR, PFS, and OS irrespective of T790M.

Julia Roeper

e20679

Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution.

Jillian Bracht

9055

Transcriptional characterization of immune microenvironment and their prediction role for the prognosis of local advanced lung adenocarcinoma.

Yuqiao Chen

e20625

Treatment and outcomes for patients (pts) with selected advanced/metastatic cancers by place of care.

Yihua Xu

e20717

Treatment beyond RECIST-defined progression in relapsed EGFR-mutated non-small cell lung cancer (NSCLC) patients treated with 2nd line osimertinib.

Inger Johanne Zwicky Eide

e20544

Treatment delay and outcomes in stage IV lung cancer: The reality of a public hospital in a developing country.

Nicolas Peruzzo

e20709

Trends in immunotherapy use and survival impact in stage IV non-small cell lung cancer.

Zachary Otaibi

e20715

Understanding biological driver mutations and mechanism of resistance to EGFR-tyrosine kinase inhibitors in lung cancer patients using a novel translational platform.

Govind K. Babu

e20555

Upfront EGFR TKI with or without brain radiotherapy (RT) in EGFR-driven non-small cell lung cancer (NSCLC) with brain metastases.

Nicolas Villanueva

e20614

Using a multiplexed immunofluorescence approach to compare immune cell populations in subtypes of non-small cell lung cancer.

Anna Juncker-Jensen

e20702

Using single cell genomics to change the treatment of lung cancer.

Venessa T. Chin

e20563

Utility of the Lung Immune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab.

Juan Ruiz Bañobre

e20645

Validation of broad panel clinical sequencing-based genomic risk stratification in patients with advanced lung adenocarcinomas.

Sam Whipple

9113

Variation in the assessment of immune-related adverse event occurrence, grade, and timing.

David Hsieh

9047

Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure.

Daniel Morgensztern

9109

Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs).

Enriqueta Felip

9071